Endometrial cancer remains the most prevalent gynecological malignancy in developed nations and is rising across urban India. Therefore, clinicians increasingly rely on comprehensive molecular profiling to guide prognosis and adjuvant management. Among diverse oncogenic alterations, KRAS-mutated endometrial carcinomas represent an important biological subset with distinct clinical trajectories. Specifically, genetic sequencing demonstrates that Kirsten rat sarcoma viral oncogene homolog mutations drive tumor initiation and progression. However, their exact clinical impact differs substantially across histological subtypes. Consequently, understanding these variations provides oncologists with critical insights to optimize patient outcomes.

Prevalence of KRAS-Mutated Endometrial Carcinomas Across Subtypes

Recent genomic investigations highlight the prevalence of activating KRAS hotspot mutations across uterine carcinomas. In a cohort of 612 endometrial cancer cases, targeted genomic sequencing identified KRAS hotspot mutations in 119 patients, representing 19.4% of tumors. Furthermore, the analysis showed that these mutations occur across diverse histological categories rather than concentrating in a single entity. Most KRAS alterations occurred in endometrioid endometrial carcinomas, accounting for 98 identified cases. In contrast, researchers detected mutations in nine mesonephric-like adenocarcinomas and twelve other rare histological variants. Codons 12 and 13 represent the primary sites of missense alterations, notably including G12D, G12V, and G12A substitutions. These point mutations impair the intrinsic GTPase activity of the KRAS protein. As a result, the MAPK signaling cascade remains persistently active, driving uncontrolled cell cycle progression. Moreover, the study demonstrates that KRAS alterations serve as early trunk mutations in some lineages while emerging as secondary subclones in others. Therefore, recognizing the baseline prevalence helps pathologists establish standardized molecular screening protocols.

Mesonephric-Like Adenocarcinoma Versus Endometrioid Carcinoma

The clinical profile of KRAS-altered tumors changes dramatically between different histological diagnoses. Specifically, patients with mesonephric-like adenocarcinoma present distinct demographic and staging parameters compared to those with endometrioid carcinoma. Women with mesonephric-like adenocarcinoma frequently present at a younger age than typical endometrioid cancer patients. However, despite their younger age, these individuals exhibit significantly more advanced FIGO stages at presentation. Additionally, mesonephric-like tumors demonstrate deep myometrial invasion and extensive lymphovascular space invasion. Endometrioid tumors harboring KRAS mutations often arise from hyperplastic precursors and follow a comparatively indolent early course. In contrast, mesonephric-like malignancies exhibit intrinsic biological aggression. Pathologists consistently observe complex tubular, glandular, and retiform growth patterns in mesonephric-like tumors. Furthermore, immunohistochemistry reveals positive staining for GATA3 and TTF-1 alongside negative estrogen receptor expression. Thus, the presence of a KRAS alteration does not confer a uniform phenotype across tumor types. Clinicians must therefore interpret KRAS status within the specific context of underlying tumor morphology.

Genomic Landscapes and Concurrent Molecular Alterations

Comprehensive genomic sequencing reveals that KRAS mutations intersect with diverse secondary genetic aberrations. In endometrioid endometrial carcinoma, KRAS alterations frequently co-occur with PTEN, PIK3CA, and ARID1A mutations. Furthermore, these tumors demonstrate a significant association with mismatch repair deficiency and high microsatellite instability. Consequently, such tumors exhibit high tumor mutational burdens, creating substantial neoantigen presentation. In contrast, mesonephric-like adenocarcinomas display a markedly distinct genomic background. They generally maintain intact mismatch repair machinery and lack the classic hypermutated phenotype. Instead, mesonephric-like carcinomas frequently display recurrent chromosomal gains on chromosome 1q along with specific PI3K pathway alterations. Notably, TP53 mutations remain rare in both KRAS-mutant endometrioid and classical mesonephric-like variants. This observation indicates that KRAS activation drives oncogenesis independently of p53 disruption in these specific subgroups. Accordingly, mapping co-mutations clarifies disease biology and prevents misclassification into incorrect prognostic risk groups. Integrating these genomic markers enables accurate molecular classification under current international guidelines.

Metastatic Patterns and Differential Clinical Behavior

The presence of KRAS mutations exerts distinct influences on tumor dissemination patterns. Endometrioid endometrial carcinomas with KRAS mutations typically progress through predictable regional lymphatic drainage basins. As a result, pelvic and para-aortic lymph nodes represent the most common metastatic sites. Mesonephric-like adenocarcinomas, however, demonstrate an unusual predilection for distant hematogenous dissemination. Specifically, clinical studies indicate that pulmonary metastases occur in up to forty-five percent of affected patients. Furthermore, recurrence can develop several years after primary curative surgical resection. This unique organotropism resembles cervical mesonephric carcinoma rather than conventional Müllerian malignancy. Additionally, patients frequently present with multi-organ involvement involving lungs, peritoneum, and distant skeletal sites. Therefore, routine surveillance protocols designed for standard endometrial cancer may fail to detect early pulmonary recurrence. Gynecologic oncologists must therefore maintain high suspicion during follow-up of mesonephric-like cases. Ordering periodic thoracic computed tomography scans provides essential lead time for early salvage intervention.

Diagnostic and Histopathological Evaluation Strategies

Accurate histopathological evaluation remains vital to distinguish KRAS-mutated mesonephric-like adenocarcinoma from low-grade endometrioid cancer. Because mesonephric-like carcinomas display varied architectural patterns, biopsy specimens frequently cause diagnostic confusion. Pathologists often encounter tubules lined by cuboidal cells containing dense eosinophilic colloid-like intraluminal secretions. However, superficial biopsies can easily mimic conventional well-differentiated endometrioid histology. Therefore, immunohistochemical staining panels provide indispensable diagnostic confirmation. Mesonephric-like tumors consistently express GATA3, thyroid transcription factor-1, and luminal CD10. Conversely, these neoplasms lack estrogen and progesterone receptor expression, unlike typical endometrioid lesions. Next-generation sequencing panels further assist in verifying KRAS mutations at codons 12, 13, or 61. In resource-conscious settings across India, reflex immunohistochemistry combined with targeted molecular testing optimizes diagnostic accuracy. Consequently, multidisciplinary tumor boards can formulate appropriate surgical staging and adjuvant therapy regimens. Implementing structured diagnostic workflows prevents understaging and ensures timely therapy initiation for aggressive subtypes.

Therapeutic Implications and Targeted Treatment Horizons

The therapeutic management of KRAS-mutated endometrial carcinomas is evolving rapidly with precision oncology. Standard systemic therapy relies on platinum-based chemotherapy combinations, primarily carboplatin and paclitaxel. However, advanced or recurrent cases often demonstrate resistance to conventional cytotoxic regimens. Fortunately, novel allele-specific direct KRAS inhibitors offer promising new therapeutic avenues. Small-molecule inhibitors targeting KRAS G12C, G12D, and pan-KRAS variants are currently undergoing extensive clinical investigation. Furthermore, when KRAS mutations co-occur with mismatch repair deficiency, immune checkpoint inhibitors achieve durable anti-tumor responses. In contrast, proficient mismatch repair tumors may benefit from combinations of MEK inhibitors and PI3K pathway inhibitors. Additionally, liquid biopsy techniques analyzing circulating tumor DNA provide non-invasive monitoring of therapeutic response and emerging resistance mutations. Clinicians should encourage eligible patients to enroll in biomarker-directed clinical trials. Ultimately, coupling molecular subtyping with mutation-specific inhibitors will transform the management landscape for refractory uterine carcinomas.

How common are KRAS mutations in endometrial cancer?

Researchers identify KRAS hotspot mutations in approximately fifteen to twenty percent of all endometrial cancer cases. These oncogenic mutations occur most frequently within endometrioid endometrial carcinomas, where they influence cellular proliferation through MAPK signaling. In addition, activating mutations appear in a high proportion of rare mesonephric-like adenocarcinomas. Identifying KRAS mutation status provides valuable diagnostic insight and helps clinicians determine appropriate molecular classification, prognostic risk stratification, and experimental targeted therapeutic choices.

Why does mesonephric-like adenocarcinoma carry a worse prognosis?

Mesonephric-like adenocarcinoma displays aggressive biological behavior compared to standard endometrioid tumors. Patients often present with advanced FIGO stage, deep myometrial invasion, and extensive lymphovascular infiltration despite their younger average age. Furthermore, this histological subtype demonstrates a striking propensity for distant hematogenous metastases, particularly to the lungs. Tumors typically lack hormone receptor expression, which limits the efficacy of endocrine therapy and necessitates aggressive multimodality systemic treatment strategies.

What targeted therapies exist for KRAS-mutated endometrial tumors?

Targeted therapeutic strategies for KRAS-mutated tumors depend on co-existing molecular alterations and specific codons. Direct small-molecule inhibitors targeting G12C and G12D alleles are currently demonstrating promise in clinical trials. Additionally, downstream MEK inhibitors combined with PI3K pathway inhibitors show active preclinical efficacy. When tumors exhibit concurrent mismatch repair deficiency, clinicians successfully utilize immune checkpoint inhibitors. Enrolling eligible patients in ongoing biomarker-driven clinical trials remains the best approach for refractory disease.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Li WQ et al. KRAS-mutated endometrial carcinomas: a comprehensive analysis of clinicopathological and molecular profiles across histological subtypes. Virchows Arch. 2026 Sep 21. doi: 10.1007/s00428-026-04723-8. PMID: 42766006.

Kilowski K et al. KRAS mutations in endometrial cancers: Possible prognostic and treatment implications. Gynecol Oncol. 2024;191:102-108. doi: 10.1016/j.ygyno.2024.10.026.

Muto H et al. Endometrial mesonephric-like adenocarcinoma: Clinicopathologic features, treatment, and outcomes. Gynecol Oncol Rep. 2025;56:101625. doi: 10.1016/j.gore.2025.101625.